Oak Brook, IL – Volume 42 of SLAS Discovery includes one review, eight original research articles and 1 short communication for oncology, infectious disease, immunology and computational biology research through innovative screening platforms for accelerating the discovery of targeted therapies, diagnostic biomarkers, and mechanistic insights across diverse disease areas.
Access to this volume of SLAS Discovery is available at https://www.slas-discovery.org/issue/S2472-5552(26)X2003-2
All active SLAS Discovery and SLAS Technology call for papers are available at: https://www.slas.org/publications/call-for-papers/
*****
SLAS Discovery reports how scientists develop and use novel technologies and/or approaches to provide and characterize computational, chemical and biological tools to understand and treat human disease. The journal focuses on drug discovery sciences with a strong record of scientific rigor and impact, reporting on research that:
SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS Discovery: Advancing the Science of Drug Discovery, 2025 Impact Factor 3.3. Editor-in-Chief Robert M. Campbell, PhD, Grove Biopharma, Inc., Chicago, IL (USA)
###
SLAS DISCOVERY